Patents/Publications

PATENTS

Issued

(1) METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE.  Patent no. US 10,159,706 B2.  Date of patent: Dec. 25, 2018

(2) COMPOSITIONS COMPRISING IL-7 RECEPTOR LIGANDS. Patent no. US9,266,937 B2. Date of patent: Feb. 23, 2016

(3) COMPOSITIONS AND METHODS FOR PURIFYING BAX.  Patent no. US 9,403,888.  Date of patent: August 2, 2016

Licensing Agreements

A licensing agreement for patents (above) has been signed with SEVA Therapeutics, Inc.

RECENT PEER-REVIEWED PUBLICATIONS 

  • Cox A, A Martini, D. Decker, L Barr, C Alemeny, R Moroose, AS Khaled and AR Khaled.   Detection of Circulating Tumor Cells from the Blood of Metastatic Breast Cancer Patients using Chaperonin- Containing TCP1 Subunit 2 (CCT2).  In preparation.
  • Ghozlan H, A Showalter, P Gopalan, AS Khaled and AR Khaled. Breast Cancer Spheroid Formation is Enhanced By Expression of Chaperonin- Containing TCP1 Subunit 2 (CCT2). In preparation.
  • Nierenberg D, Flores O, Fox D, Sip YYL, Finn C, Ghozlen H, Cox A, McKinstry KK, Zhai Land, Khaled AR. 2020. Protein corona formation in the modulation of transendothelial transport and the tumor biodistribution of polymeric nanoparticles. Submitted to Int J Nano.
  • Showalter AE, AC Martini, D Nierenberg, K Hosang, NA Fahmi, P Gopalan, AS Khaled, W Zhang, and AR Khaled. 2020. Investigating Chaperonin-Containing TCP-1 subunit 2 as an essential component of the chaperonin complex for tumorigenesis. Scientific Reports. 10, Article number:798 (2020).              Showalter Sci Rep 2020
  • Doshi M, O Flores-Fernandez*, P Deme, D Nierenberg*, AR Khaled, and S Parthasarathy.   2019              Cypate and cypate-glucosamine as near infrared (NIR) fluorescent probes for imaging. Mol Pharm. 95(5):475-489.  Doshi Mol Pharm 2019
  • Xin LI; Naser SA, Khaled A, Hu H, Li X. 2018. When old metagenomic data meet newly sequenced genomes, a case study. PLoS One. 13(6):e0198773  Li Plos One 2019
  • Nierenberg D*, O Flores* and AR Khaled. 2018. Formation of a Protein Corona Influences the Biological Identity of Nanomaterials. Reports of Practical Oncology and Radiotherapy. Invited Review. 23(4):300-308. Niernberg RPOR 2018
  • Mozayan A* and AR Khaled. 2018. Elucidation of Therapeutic Peptide Binding Partners from Isolated Mitochondria. Cureus 10(6): e2898.  Mozayan Cureus 2018
  • Carr A*, AS Khaled, R Bassiouni*, O Flores*, D Nierenberg*, H Bhatti, P Vishnubhotla, JM Perez, S Santra, and AR Khaled. 2017. Targeting Chaperonin Containing TCP1 (CCT) as a Molecular Therapeutic for Small Cell Lung Cancer. Oncotarget.  8(66):110273-88.  Oncotarget
  • Showalter A*, A Limaye*, JL Oyer, R Igarashi, C Kittipatarin*, AJ Copik, and AR Khaled. 2017. Cytokines in Immunogenic Cell Death: Applications for Cancer Immunotherapy. Cytokine. 97:123-132.  Cytokine
  • Flores O*, S Santra,C Kaittanis, R Bassiouni*, AS Khaled, AR Khaled, J Grimm, and JM Perez. 2017. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.  Theranostics. 7(9):2477-2494. Theranostics
  • Bassiouni R*, K Nemec*, A Iketani, O Flores*, A Showalter*, RW Sprung, C Kaittanis, P Vishnubhotla, AS Khaled, JM Perez, AR Khaled. 2016.  Chaperonin containing-TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide.  Clin Cancer Res. 22(17):4366-79  Clinical Cancer Research
  • Lee MW, R Bassiouni*, A Iketani, JM Perez and AR Khaled. 2014.  The CT20 peptide:  More than a piece of Bax. Cancer Cell and Microenvironment.  1:e266  Lee CCM 2014
  • Lee MW, R Bassiouni*, NA Sparrow*, A Iketani, RJ Boohaker*, C Moskowitz*, P Vishnubhotla, AS Khaled, J Oyer, A Copik, C Fernandez-Valle, JM Perez and AR Khaled. 2014. The CT20 Peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption.  Cell Death and Disease.   22:5 e1249   Lee CDD 2014
  • Garg P*, KN Nemec, AR Khaled, SA Tatulian. 2013. Transmembrane pore formation by the carboxyl terminus of Bax protein. Biochim Biophys Acta. 1828(2):732-42
  • Tatulian SA, P Garg*, KN Nemec, AR Khaled.   Molecular basis for membrane pore formation by Bax protein carboxyl terminus.  Biochemistry 51(46):9406-19
  • Ruppert SM*, W Li, G Zhang*, AL Carlson, A Limaye*, SK Durum, AR Khaled. 2012. The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes. Biochim Biophys Acta. 1823(10):1877-93.
  • Boohaker RJ*, G Zhang*, MW Lee, KN Nemec, S Santra, JM Perez, AR Khaled. Rational development of a cytotoxic peptide to trigger cell death. Mol Pharm. 9(7):2080–93  Boohaker Mol Pharm 2012
  • Boohaker RJ*, MW Lee, P Vishnubhotla, JM Perez, AR Khaled. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 1;19(22):3794-804.
  • Altomare DA, AR Khaled. 2012. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem.1;19(22):3748-62.
  • Ruppert SM*, M Chehtane*, G Zhang*, H Hu, X Li, AR Khaled.  JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction.  PLoS One.2012;7(2):e32262. Epub 2012 Feb 23.
  • Boohaker RJ*, G Zhang*, A Loosely, KN Nemec* and AR Khaled. BAX supports the mitochondrial network, promoting bioenergetics in Non-Apoptotic Cells. AJP: Cell Physiology. 300(6):C1466-1478.
  • Kittipatarin C*, W Li, SK Durum, AR 2010. Cdc25A-driven proliferation regulates CD62L levels and lymphocyte movement in response to interleukin-7. Exp Hematol. 38(12):1143-56]
  • Kittipatarin C*, N Tschammer* and AR Khaled. The Activity of LCK upon STAT5 can differentially modulate Interleukin-7 signaling in CD4 and CD8 T cells. Immunol Letts. 131(2):170-81.
  • Chehtane M* and AR Khaled. 2010. Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the Hexokinase II gene expression. AJP: Cell Physiol 298(6):C1560-71.
  • Kittipatarin C* and AR Khaled. Ex vivo expansion of memory CD8 T-cells from lymph nodes or spleen through in vitro culture with interleukin-7. J. Immunol Methods. 15;344(1):45-57.
  • Nemec KN* and AR Khaled. 2008. Therapeutic Modulation of Apoptosis: Targeting the BCL2 family at the interface of the mitochondrial membrane. Yonsei Med J. 49(5):689-97.
  • Grenier AD*, K Abu-ihweij*, G Zhang*, S Ruppert*, RJ Boohaker*, E Slepkov, K Pridemore, JJ Ren, L Fliegel, and AR Khaled. 2008. Apoptosis-induced alkalinzation by the Na+/H+ exchanger isoforms 1 is mediated through phosphorylation of amino acids Ser726 and Ser729.   Am J Physiol Cell Physiol.295(4):C883-96.
  • Kaur N, J Delcros, M Chehtane*, N Tschammer*, A Khaled and O Phanstiel. A comparison of Chloroambucil- and Xylene-containing polyamines leads to improved ligands for accessing the polyamine transporter. J. Med. Chem. 51(5):1393-401.
  • Kittipatarin C* and AR Khaled. Interlinking Interleukin-7. Cytokine 39:75-83.
  • Xie S, P Cheng, G Liu, Y Ma, J Zhao, M Chehtane*, AR Khaled, O Phantstiel, and C Wang.   Synthesis and bioevaluation of the N-(Arylalkyl)-homospermidine conjugates.  BMCL  17(16):4471-5.
  • Iacovelli J, J Lopera, M Bott, E Baldwin, A Khaled, N Uddin, and C Fernandez-Valle. 2007. Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27 expression. GLIA 55(16):1638-47..
  • Kittipatarin C*, W.Q. Li, D Bulavin, SK Durum and R. Khaled. 2006.  Cell Cycling Through Cdc25A:Transducer of Cytokine Proliferative Signals.  Cell Cycle. 5:907-12.
  • Li WQ, Q Jiang, E Aleem, P Kaldis, AR Khaled, SK Durum. 2006. IL-7 promotes T cell proliferation through destabilization of p27Kip1.  J Exp Med. 203(3):573-82.
  • Kotha A, M Sekharam, L Cilenti, K Siddiquee, A Khaled, AS Zervos, B Carter, J Turkson and R Jove. Resveratrol inhibits Src and Stat3 and induces the apoptosis of malignant cells containing activated Stat3.   Mol Can Ther. (3):621-9.
  • Khaled A, S Guo, F Li, P Guo.   Controllable Self-Assembly of Nanoparticles for Specific Delivery of Multiple Therapeutic Molecules to Cancer Cells Using RNA Nanotechnology.  Nano Lett. 14;5(9):1797-1808
  • Jiang Q, WQ Li, FB Aiello, R Mazzucchelli, B Asefa, AR Khaled, SK Durum. 2005. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 16(4-5):513-33.
  • Khaled AR, DV Bulavin, C Kittipatarin*, WQ Li, KM. Alvarez, K Kim, HA Young, AJ Fornace, and SK Durum.   Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biology 169[5]:755-63.
  • Jiang Q, WQ Li, RR Hofmeister, HA Young, DR Hodge, JR Keller, AR Khaled, SK Durum. 2004. Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol Cell Biol. 24(14):6501-13.
  • Ashktorab H, S Frank, AR Khaled, S Durum, B Kifle, and DT Smoot. 2004. Bax translocation and mitochondrial fragmentation induced by H. pylori. Gut  53:805-13.
  • Li WQ, Q Jiang, AR Khaled, JR Keller, and SK Durum. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival.  J Biol Chem. 279(28):29160-6
  • Jiang Q, N Benbernou, O Chertov, AR Khaled, J Wooters and SK Durum. 2004. IL-7 induces tyrosine phosphorylation of clathrin heavy chain.  Cell Signal 16:281-6.
  • Khaled AR and SK Durum. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol. Rev. 193(1) :48-57.
  • Kim K, AR Khaled, D Reynolds, HA Young, CK Lee, and SK Durum. Characterization of an interleukin-7-dependent thymic cell line derived from a p53-/- mouse.  J Immunol. Methods  274:177-184.